Novo Nordisk's Once-Weekly Insulin Flagged With Risk Of Low Blood Sugar Ahead Of FDA Review
Yahoo Finance · 4 days ago
Open | 134.50 |
High | 136.70 |
Low | 134.22 |
Mkt Cap | 606.01B |
P/E (TTM) | 47.24 |
Div & Yield | 1.37 & 1.01% |
Prev. Close | 135.57 |
52 Wk. Low | 75.56 |
52 Wk. High | 138.28 |
Related stocks
Danish pharmaceutical company
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd with production facilities in nine countries and affiliates or offices in five countries. Wikipedia
(USD) | Q1 2024 | Y/Y |
---|---|---|
Revenue | 65.35B | 22.50% ▲ |
Net Income | 25.41B | 28.20% ▲ |
Diluted EPS | 0.82 | 29.40% ▲ |
Quarter | EPS Estimate | EPS Actual |
---|---|---|
Q2 2024 | $0.81 | - |
Q1 2024 | $0.74 | $0.82 |
Q4 2023 | $0.64 | $0.70 |
S&P 500^GSPC | 5,304.72+36.88 (+0.70%) |
Dow 30^DJI | 39,069.59+4.29 (+0.01%) |
Nasdaq^IXIC | 16,920.79+184.79 (+1.10%) |
Ethereum USDETH-USD | 3,860.01+3.02% |
364.60+0.34% | |
7.21-2.83% |